Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors

Figure 2 Relation between serum microRNA-122 level and other laboratory parameters. A: Differences of serum microRNA-122 (miR-122) in relation to alanine aminotransferase (ALAT) [ALAT normal: ≤ 0.58 (w) / 0.83 (m) μmol/Ls, ALAT pathological: > 0.58 (w) / 0.83 (m) μmol/Ls]; B: Differences of serum miR-122 in relation to aspartate aminotransferase (ASAT) [ASAT normal: ≤ 0.58 (w) / 0.83 (m) μmol/Ls, ASAT pathological: > 0.58 (w) / 0.83 (m) μmol/Ls]; C: Differences of serum miR-122 in relation to alpha-fetoprotein (AFP) (AFP normal: AFP < 7 ng/mL, AFP slightly increased: 7 ng/mL ≤ AFP ≤ 400 ng/mL, AFP clearly increased: AFP > 400 ng/mL); D: Differences of serum miR-122 in relation to creatinine [Crea normal: ≤ 84 (w) / 104 (m) µmol/L, Crea pathological: > 84 (w) / 104 (m) µmol/L]; E: Differences of serum miR-122 in relation to hemoglobin [Hb normal: ≥ 7.4 (w) / 8.6 (m) mmol/L, Hb pathological: < 7.4 (w) / 8.6 (m) mmol/L]. Mann-Whitney test, Kruskal-Wallis test and post-hoc Dunn’s test were used for statistical analysis. ^aP < 0.05 and ^bP < 0.01 vs normal group, not significant- not shown. ASAT: Aspartate aminotransferase; ALAT: Alanine aminotransferase; AFP: Alpha-fetoprotein; Crea: creatinine.